March 9, 2012. When oral contraceptives first became available, comparing risks and benefits of oral contraceptives to pregnancy was the right question.
Read More »On Medical Treatments & Products
NCHR Testimony on Classification for Cranial Electrotherapy Stimulators
February 10, 2012. This testimony supported the FDA’s position that the available scientific evidence does not support reclassifying Cranial Electrotherapy Stimulators to a medical device category with lower risk.
Read More »FDA Needs to Provide Breast Implant Patients and Physicians with Unreported Industry Data About Quality of Life, Connective Tissue Symptoms, Rupture Rates Per Patient, and Other Complications
January 5, 2012. At the FDA Advisory Panel meetings in 2003 and 2005, FDA provided and presented data from the Breast Implant Core studies regarding connective tissue disorder (CTD) signs and symptoms (S/S) and Quality of Life measures.
Read More »Statement of Dr. Diana Zuckerman, Yasmin, Yaz and Other Drospirenone Birth Control Products
December 8, 2011. Dr. Diana Zuckerman spoke at the FDA meeting on the safety of Bayer’s birth control pills Yasmin and Yaz and other drospirenone birth control products, advocating for these high risk drugs to be taken off the market.
Read More »NCHR Testimony at the Senate Aging Committee Hearing on Atypical Antipsychotic Drugs
November 30, 2011. Dr. Diana Zuckerman, the president of NRC, provided a statement for the Senate Aging Committees regarding problems with antipsychotic drugs.
Read More »